The Deal’s Post

Drug combination therapy & Drug repositioning .. the direction where Science is heading

Unity makes strength, and strength is needed to serve patients! 💪🚀 #AmgenProud The five key takeaways: 1- Combined capabilities strengthen portfolio of innovative therapeutics that are first-in-class 2- Leverages Amgen's global footprint, world-class manufacturing, and experience with products early in their lifecycle 3- Reinforces Amgen's leadership expertise and long track record of developing and commercializing rare disease products in inflammation and nephrology 4- Enables a sustained investment in R&D innovation for long-term growth 5- Furthers our mission to serve patients living with serious illnesses, including rare diseases

Today, Denali joins top experts in science, advocacy, drug development, and policy at the Reagan-Udall Foundation for the FDA workshop, Qualifying Biomarkers to Support Rare Disease Regulatory Pathways. Together, we will discuss the urgent need to accelerate delivery of promising therapies to families living with rare neurodegenerative disorders. Learn more here: https://lnkd.in/ebQuRN44

Old advertising tips from 1995:📚 𝗜 𝗹𝗲𝗮𝗿𝗻𝗲𝗱 𝘁𝗵𝗶𝘀 𝗮𝘁 𝘂𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗶𝗻 𝟭𝟵𝟵𝟱: • We are flooded with information.🌊 • We can take in only a little part of this information. • Our brains can only keep a bit of this information.🧠 • Reading is slow: We read one word at a time, and it takes time. • Pictures are quick: We see all of a picture at once.👀 • So pictures are better than text at showing feelings and information. ➡️ 𝗣𝗶𝗰𝘁𝘂𝗿𝗲𝘀 𝗮𝗻𝗱 𝘃𝗶𝗱𝗲𝗼𝘀 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗯𝗲𝘀𝘁 𝗳𝗼𝗿: • Getting attention.👁️ • Spark emotions. • Entertain.🎭 •  Remembering the information.    ➡️ 𝗪𝗵𝗮𝘁 𝗜 𝗹𝗲𝗮𝗿𝗻𝗲𝗱 𝗶𝗻 𝟭𝟵𝟵𝟱 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘁𝗿𝘂𝗲 𝘁𝗼𝗱𝗮𝘆! Mark Bleackley knows this!🌟 He just started showing the video we made for him. To grab the attention of investors and the public! Thanks, Mark! Have a happy Friday, everyone! 𝗣.𝗦. 𝗗𝗼 𝘆𝗼𝘂 𝗳𝗲𝗲𝗹 𝗼𝘃𝗲𝗿𝘄𝗵𝗲𝗹𝗺𝗲𝗱 𝗯𝘆 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗼𝘂𝘁 𝘁𝗵𝗲𝗿𝗲, 𝘁𝗼𝗼?

Real Stories, Remarkable Results 📣 Hear how practices like yours are thriving with our seca and inHealth Lifestyle Therapeutics partnership. Their stories are just the beginning. Ready to write your own? Start with us. #secaInHealth #SuccessStories https://hubs.li/Q02h4tkl0

Despite significant changes in treatment options over the past decade, MM patients still face inevitable relapse. Confirmative trials typically last 5+ years, focusing on PFS (primary endpoint) and OS (key 2nd endpoint). With MRD as an early endpoint, new treatments could reach patients sooner. MRD testing is well-established for MM and correlates directly with disease burden. We eagerly await detailed FDA guidance, especially regarding single-arm studies and another early endpoint, objective response rates. Additionally, FDA expanded approval for two CAR T-cell therapies as earlier treatment options for Relapsed/Refractory MM. Despite concerns from CBER about early deaths, the ODAC committee views these risks as manageable. Personally, I remain skeptical about the overall survival benefit of BMS/Celgene therapy due to high crossover rates. Overall, this April brings new hope for MM patients and oncology professionals.

Tomorrow, February 29, it’s #RareDiseaseDay. In 1983, #OrphanDrugAct was passed and brought more resources toward the research, development, and distribution of #RareDisease therapeutics. 41 years later, we celebrate the continued progress and hope within the rare disease community! If you want to support anyone with a #RareDisease, you can learn more here: bit.ly/RDD2024 #RareDiseaseDay, #LightUpForRare, #ShareYourColors, #ShowYourStripes

On July 3rd, we’ll join CureDuchenne for a webinar about the efficacy and safety data from the DELIVER trial of DYNE-251, an investigational therapeutic for people with #DMD amenable to exon 51 skipping: https://bit.ly/3zvfpTf #clinicaltrial #drugdevelopment

Another important step completed - with some valuable experience of the new(ish) CTIS clinical trial approval system gained along the way!